drugset / Trial / NCT00979706
Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).
RandomizedParallel-groupOpen-labelTreatment
Summary
Pilot study for the treatment of primary HIV infection with the objective to induce a strong specific HIV immune response able to control viral replication without HAART.
Timeline
- Start
- 2005-03
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 250 ug/ml | Oral |
| Subject | Cyclosporine | Peptide | 350 ug/ml | Oral |
| Subject | GM-CSF | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | Peg-IFN | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 750000 iu/kg | Subcutaneous |
| Comparator | Kaletra | Unknown | — | — |
| Comparator | Lamivudine | Other / unclassified | — | — |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Comparator | Trizivir | Unknown | — | — |